50 results about "Hepatitis B infection" patented technology

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and / or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and / or prevention of a HBV infection.

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

The invention relates to methods and compositions for treating hepatitis B infection. Disclosed is a biological nanoparticle (BNP) comprising a hepatophilic DNA virus envelope HBsAg-S fusion protein comprising one or more epitope regions wherein the epitope regions are selected from the group consisting of epitopes expressed in the Ring 1 region and the Ring 2 region of the HBsAg-S domain, and wherein the epitope regions comprise one or more of CTKPTDGNC (SEQ ID NO: 34) and / or CKTCTTPAQGNSMFPS (SEQ ID NO: 35).

To solve a problem of presence of need for improvement in treating a chronic hepatitis B patient, particularly treatment capable of extracting enhancement of cellular immune response in a subject despite long exploration of a vaccine to hepatitis B infection.SOLUTION: Provided is a composition and a method useful for inducing Th1 cell response in a subject affected with hepatitis B. As described in the specification, the composition contains HBsAg having S-protein, Pre-S1 protein and Pre-S2 protein, and aluminum phosphate adjuvant. In a preferable embodiment, an immunogenic composition contains at least 20 μg / mL of HBsAg antigen, and the amount of non-adsorptive antigen is at least 30%.SELECTED DRAWING: None

The invention discloses a lentiviral vector and lentiviral vector particles for treating hepatitis B infection. The lentiviral vector and particles of the invention contain a nucleotide sequence coding an hepatitis B virus antigen. The large S antigen of hepatitis B virus was in particular selected as candidate and can be applied in pharmaceutical compositions or vaccines for treating and / or preventing hepatitis B virus infection or treating and / or preventing diseases caused by hepatitis B virus infection, which has excellent therapeutic and preventive effects in subjects in need thereof.

To identify novel nucleic acid molecules that can inhibit the expression of both PAPD5 and PAPD7 in vivo and in vitro.SOLUTION: The present invention provides a nucleic acid molecule that is complementary to both PAP-related domain-containing 5 (PAPD5) and PAP-related domain-containing 7 (PAPD7), and inhibits the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The present invention also provides PAPD5 and PAPD7 specific nucleic acid molecules used for the treatment and / or prevention of HBV infections, especially chronic HBV infections. Also included in the present invention are pharmaceutical compositions for use in the treatment and / or prevention of HBV infections.SELECTED DRAWING: Figure 3

A piezoelectric plate sensor comprising a piezoelectric layer; two electrodes; and an insulation layer. The insulation layer is produced by soaking the piezoelectric layer and two electrodes in a mercaptopropyltrimethoxysilane solution with an amount of water from 0.1 v / v. % to about 1 v / v % and at pH from about 8 to about 150 for a period from about 8 to about 15 hours, and the mercaptopropyltrimethoxysilane solution has a concentration of mercaptopropyltrimethoxysilane from about 0.01 v / v % to about 0.5 v / v %. A method of detecting a biomolecule in a sample using the piezoelectric plate sensor in particular, that of detecting a genetic marker with PCR sensitivity and specificity without the need of DNA isolation or amplification is also provided. The piezoelectric plate sensor may be used to diagnose various diseases including breast cancer, myocardial infarction, diarrhea, Clostridium difficile infection, and hepatitis B infection.

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

The invention relates to a saponin conjugate comprising a saponin covalently linked to a ligand for ASGPR, the ligand comprising at least one GalNAc. The invention also relates to a pharmaceutical combination comprising a first pharmaceutical composition comprising the saponin conjugate of the invention and a second pharmaceutical composition comprising a second conjugate of an effector molecule and a ligand for ASGPR, or a third conjugate of an effector molecule and a binding molecule for binding to a cell-surface molecule. In addition, the invention relates to a pharmaceutical composition comprising the saponin conjugate of the invention and the second conjugate or the third conjugate. Furthermore, the invention relates to a pharmaceutical combination or pharmaceutical composition of the invention, for use as a medicament. The invention also relates to a pharmaceutical combination or pharmaceutical composition of the invention, for use in the treatment or prophylaxis of a disease or health problem in which an expression product is involved of genes: apoB, TTR, PCSK9, ALAS1, AT3, GC, CC5, X gene of HBV, S gene of HBV, AAT and LDH, and for use in the treatment or prophylaxis of a cancer, an infectious disease, a viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, AAT related liver disease, acute hepatic porphyria, TTR amyloidosis, complement-mediated disease, hepatitis B infection, or an auto-immune disease. Finally, the invention relates to an in vitro or ex vivo method for transferring the second conjugate or the third conjugate of the invention from outside a cell to inside said cell.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

This application belongs to the field of immunoassay technology, specifically relating to specific binding proteins of hepatitis B viruses (MHBs), nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides a specific binding protein of MHBs with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with large and small proteins, thus improving detection specificity and avoiding false positive results. The specific binding protein of MHBs in this application can bind to a chemiluminescent detection system, thereby achieving highly sensitive detection of MHB antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

This application belongs to the field of immunoassay technology, specifically relating to LHBs-specific binding proteins, nucleic acid molecules, vectors, cells, detection kits, and their preparation methods and applications. This application provides an LHBs-specific binding protein with specific CDRs, exhibiting high affinity and specificity. It solves the problem in existing technologies of being unable to distinguish between large, medium, and small hepatitis B virus proteins, and ensures that the antibody does not cross-react with medium and small proteins, thus improving detection specificity and avoiding false positive results. The LHBs-specific binding protein of this application can bind to chemiluminescent detection systems, thereby achieving highly sensitive detection of LHBs antigen levels in clinical samples, with high consistency with nucleic acid detection results, providing an important tool for monitoring hepatitis B infection status and disease progression.

The present invention relates to an alternative method for synthesizing a compound of formula (I) or a pharmaceutically acceptable salt or diastereomer thereof, R 1 is phenyl, which is unsubstituted or substituted by one, two or three independently selected from halogen and C 1‑6 Alkyl substituents are substituted; R 2 C 1‑6 Alkyl; R 3 C x H 2x ‑; x is 1, 2, 3, 4, 5, 6 or 7; the compound or its pharmaceutically acceptable salt or diastereomer can be used to prevent and treat viral diseases associated with hepatitis B infection or diseases caused by hepatitis B infection in patients.

The present invention relates to antibodies and antigen-binding fragments thereof directed against hepatitis B virus surface antigen (HBsAg), and methods of making and using the neutralizing antibodies and antigen-binding fragments thereof. The antibody provided by the invention is derived from a hepatitis B vaccinator and a hepatitis B infection convalescent person, shows an excellent effect in the aspect of identifying different hepatitis B virus surface antigens, and has more advantages in the aspects of neutralizing hepatitis B virus mutants and reducing hepatitis B mutant antigens.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The invention relates to methods and compositions for treating hepatitis B infection. Disclosed is a biological nanoparticle (BNP) comprising a hepatophilic DNA virus envelope HBsAg-S fusion protein comprising one or more antigen epitope repeat regions wherein the one or more antigen epitope repeat regions comprise: (a) at least one dimer or trimer of an antigen epitope, wherein the dimer or trimer of the antigenic epitope comprises an antigenic epitope having an amino acid sequence selected from the group consisting of: an amino acid sequence consisting of PCKTCTTP (SEQ ID NO: 28); the amino acid sequence is composed of PCRTCTTP (SEQ ID NO: 33); an amino acid sequence consisting of CTKPTDGNC (SEQ ID NO: 34); an amino acid sequence consisting of CTKPSDGNC (SEQ ID NO: 54); the amino acid sequence is composed of PCRTCMTT (SEQ ID NO: 55); the amino acid sequence is composed of PCRTCMTTAQGTSMYPS (SEQ ID NO: 48); or (b) a first antigen epitope having an amino acid sequence consisting of PCRTCMTTAQGTSMYPSCCCTKPSDGNC (SEQ ID NO: 39) and a second antigen epitope having an amino acid sequence consisting of PCKTCTTPAQGNSMFPSCCCTKPTDGNC (SEQ ID NO: 40), as well as a preparation method and application thereof.

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC) / cirrhosis development and progression may be used in the screening of compounds useful in the treatment and / or prevention of cirrhosis and / or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and / or the prevention of HCC / cirrhosis.

The invention relates to a hepatitis B prevention and control big language model construction method, which realizes an intelligent response mechanism for automatically switching a health education mode or a clinical decision support mode based on user role attributes by integrating evidence-based medical knowledge related to hepatitis B prevention and control and retrieving an integrated system for enhanced generation and fine tuning, and provides a medical evidence tracing function. The accuracy and verifiability of hepatitis B prevention and control information are improved, off-line deployment on edge computing equipment is supported, and the life cycle of a model is prolonged. The problems that a general large model is inaccurate in knowledge, single in service mode, untraceable in conclusion and the like in the field of hepatitis B prevention and control medicine are solved, the accuracy, individuation and clinical credibility of hepatitis B prevention and control information are improved, and reliable evidence-based support is provided for full-period management of hepatitis B infected persons.

The present invention relates to a process for synthesizing a compound of formula (I), or a pharmaceutically acceptable salt thereof, which is useful for prophylaxis and treatment of a viral disease in a patient relating to hepatitis B infection or a disease caused by hepatitis B infection.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.